Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fate Therapeutics (FATE) EBT Margin (2016 - 2025)

Fate Therapeutics (FATE) has disclosed EBT Margin for 14 consecutive years, with 2374.07% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin rose 73744.0% year-over-year to 2374.07%, compared with a TTM value of 2056.15% through Dec 2025, down 64035.0%, and an annual FY2025 reading of 2056.15%, down 64035.0% over the prior year.
  • EBT Margin was 2374.07% for Q4 2025 at Fate Therapeutics, down from 1847.21% in the prior quarter.
  • Across five years, EBT Margin topped out at 42.21% in Q1 2023 and bottomed at 6236.23% in Q2 2023.
  • Average EBT Margin over 5 years is 1520.61%, with a median of 1076.97% recorded in 2024.
  • The sharpest move saw EBT Margin crashed -579226bps in 2023, then surged 564178bps in 2024.
  • Year by year, EBT Margin stood at 404.74% in 2021, then surged by 66bps to 138.74% in 2022, then plummeted by -1778bps to 2605.07% in 2023, then decreased by -19bps to 3111.51% in 2024, then increased by 24bps to 2374.07% in 2025.
  • Business Quant data shows EBT Margin for FATE at 2374.07% in Q4 2025, 1847.21% in Q3 2025, and 1785.37% in Q2 2025.